<DOC>
	<DOCNO>NCT00416897</DOCNO>
	<brief_summary>RATIONALE : Dexamethasone use treat multiple myeloma . Drugs use chemotherapy may stop growth cancer cell , either kill cell stop dividing . Plasma exchange process certain cell separate plasma blood machine cell return patient . Dexamethasone plasma exchange may effective treatment acute kidney failure cause multiple myeloma . It yet know whether give dexamethasone chemotherapy together plasma exchange effective give dexamethasone chemotherapy alone treat patient multiple myeloma acute kidney failure . PURPOSE : This randomized phase III trial study dexamethasone , chemotherapy , plasma exchange see well work compare dexamethasone chemotherapy alone treat patient newly diagnose multiple myeloma acute kidney failure .</brief_summary>
	<brief_title>Dexamethasone Chemotherapy With Without Plasma Exchange Patients With Newly Diagnosed Multiple Myeloma Acute Kidney Failure</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare effect dexamethasone cytotoxic chemotherapy v without plasma exchange likelihood renal recovery ( i.e. , dialysis-independent 100 day ) patient newly diagnose multiple myeloma acute renal failure . Secondary - Compare overall survival patient treat regimen . - Compare quality life patient treat regimen . - Determine value renal histology predict recovery renal function patient . - Determine value serum free light chain assay determine disease response renal function recovery patient . OUTLINE : This randomize , control , open-label , multicenter study . Patients stratify accord plan chemotherapy ( vincristine doxorubicin hydrochloride ( VA ) VA-like chemotherapy v thalidomide-containing chemotherapy v alkylating agent v ) , frequency chemotherapy course ( 1-3 weekly v 4 weekly ) , need dialysis randomization ( yes v ) , age ( &lt; 65 year vs ≥ 65 year ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive oral dexamethasone , least twice daily , day 1-4 9-12 . Patients undergo plasma exchange cytocentrifugation plasmafiltration 2-3 hour week 1 2 ( 7 treatment total ; 4 week 1 ) . Patients receive plan chemotherapy per local clinician day 17-100 . Chemotherapy may continue 100 day discretion local clinician . - Arm II : Patients receive dexamethasone plan chemotherapy arm I . Quality life assess baseline , day 100 , 6 12 month . After completion study treatment , patient follow 6 12 month annually thereafter . Peer Reviewed Funded Endorsed Cancer Research UK PROJECTED ACCRUAL : A total 280 patient accrue study .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Newly diagnose multiple myeloma ( MM ) , meet ≥ 2 follow criterion : Serum urine* paraprotein Bone marrow show &gt; 10 % plasma cell Lytic bone lesion NOTE : *The presence typical myeloma kidney renal biopsy consider equivalent demonstration urine paraprotein electrophoresis Acute renal failure attributable MM , meet follow criterion : Creatinine &gt; 5.65 mg/dL OR urine output &lt; 400 mL/day OR require dialysis Unresponsive treatment fluid and/or treatment hypercalcemia bisphosphonates No significant intrinsic renal disease unrelated MM PATIENT CHARACTERISTICS : Platelet count ≥ 50,000/mm³ Bilirubin ≤ 1.5 time upper limit normal ( ULN ) ALT AST ≤ 2.5 time ULN No contraindication study medication , include follow : Active recent peptic ulcer Known significant cardiac insufficiency Allergy study medication Not pregnant nursing Fertile patient must use effective contraception No known HIV positivity PRIOR CONCURRENT THERAPY : No prior chemotherapy MM Prior steroid therapy ≤ 3 day duration MM allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2007</verification_date>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
	<keyword>renal failure</keyword>
</DOC>